CureVac

Company snapshot

Headquarters of CureVac in [Tübingen](en.wikipedia.org/wiki/T%C3%BCbingen) CureVac is a [biopharmaceutical](en.wikipedia.org/wiki/Biopharmaceutical) company based in [Tübingen, Germany](en.wikipedia.org/wiki/T%C3%BCbingen) that develops [therapies based on messenger RNA](en.wikipedia.org/wiki/Nucleoside-modifie)(mRNA). With approximately 375 employees in 2018, it was founded in 2000 by Ingmar Hoer

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CureVac. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for CureVac.

1. Jun 8, 2026 Clinical update

   CV-HNLC-001 — Phase 1

View all clinical trial activity →

• What is CureVac?

  CureVac AG is a pharma organization headquartered in EU. Primary therapeutic focus areas include metastatic squamous non-small cell lung cancer. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTria

• Is CureVac publicly traded?

  CureVac appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does CureVac develop or market?

  We link 2 drug profile(s) where CureVac is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/curevac-ag#company-drugs.

• What are the latest developments for CureVac?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CureVac focus on?

  CureVac focuses on metastatic squamous non-small cell lung cancer based on our analysis of their pipeline programs and drug development activities.